Transverse Medical Inc. Successfully Completes Series B2 Financing Round to Advance Stroke Prevention Technology
A pioneering early-stage medical device company specializing in Cerebral Embolic Protection (CEP) for stroke prevention during Transcatheter Aortic Valve Replacement (TAVR) procedures, today announced the successful completion of its Series B2 capital raise. The company secured over $10 million in new funding, marking a major milestone in its growth trajectory and technological development roadmap.
The financing round was led by the company’s longstanding Legacy Lead investor, a prominent and sophisticated Family Office renowned for its strategic investments in high-impact healthcare innovations. Participation from existing Series B1 investors further validated the strength of Transverse Medical’s vision, technology platform, and management team. This latest infusion of capital reflects growing market confidence in the company’s efforts to address one of the most significant clinical challenges associated with cardiovascular interventions: reducing the incidence of periprocedural stroke and brain injury.
Advancing the Clinical Validation of Point-Guard™
Proceeds from the Series B2 round will be primarily directed toward advancing the clinical validation of Point-Guard™, Transverse Medical’s proprietary Cerebral Embolic Protection (CEP) platform. Point-Guard is currently undergoing evaluation in a Feasibility Clinical Study at the prestigious Victorian Heart Hospital in Melbourne, Australia.
The study, conducted under strict regulatory oversight, is focused on assessing the device’s safety, efficacy, and usability in real-world TAVR procedures, where the risk of embolic debris traveling to the brain remains a persistent and serious concern. Early clinical results have shown promising indicators of improved embolic protection compared to existing solutions, bolstering enthusiasm among physicians and potential future commercial partners.
In addition to ongoing clinical research, the funds will also fuel product refinement, regulatory submissions, and preparation for a pivotal trial in anticipation of FDA Investigational Device Exemption (IDE) approval. These strategic steps will move Transverse Medical closer to its long-term goal of commercializing Point-Guard as a new standard of care in structural heart procedures.
Building Operational Infrastructure for the Next Phase of Growth
Beyond product development and clinical validation, Transverse Medical plans to strategically allocate Series B2 funds toward building its internal infrastructure. The company is actively scaling its engineering, regulatory affairs, quality assurance, and operational teams to support the complex demands of clinical trials, regulatory interactions, and future commercialization activities.
Strengthening these internal capabilities will be crucial as Transverse Medical transitions from a clinical-stage innovator to a fully integrated medical device company poised for significant growth. The company’s leadership has emphasized that investing early in talent and operational excellence will enable it to maintain high standards of safety, efficacy, and compliance as it expands its presence in the global cardiovascular market.
The Unmet Need: Stroke Prevention During TAVR
TAVR procedures have revolutionized the treatment of severe aortic stenosis, offering patients a less invasive alternative to traditional open-heart surgery. However, despite advancements, one of the most concerning complications associated with TAVR remains the risk of periprocedural stroke, which can occur when embolic debris generated during the procedure travels to the brain.
Current embolic protection devices have made strides in reducing this risk but often fall short in providing comprehensive or full-brain protection. Transverse Medical’s Point-Guard is specifically engineered to address these shortcomings. Its innovative design aims to prevent all embolic particles, regardless of size, from reaching the brain’s vasculature during TAVR, thus offering what the company refers to as “Full Brain Protection™.”
By providing broader and more reliable protection, Point-Guard has the potential to significantly improve clinical outcomes, reduce hospital stays, lower healthcare costs, and ultimately enhance the quality of life for patients undergoing transcatheter cardiovascular interventions.
Leadership Perspective
Speaking about the importance of the successful financing round, Eric Goslau, President, CEO, and Co-Founder of Transverse Medical, stated:
“This successful raise marks a significant milestone for Transverse Medical and reflects strong investor confidence in our technology and mission. The continued support from our Legacy Lead investor and Series B1 investors is a testament to the urgency of the problem we are solving and the potential impact our solution can have on patient outcomes.”
Goslau continued:
“With this funding secured, we are now well-positioned to accelerate the development of our Point-Guard Protected™ solution, build critical operational capabilities, and prepare for pivotal clinical studies and FDA submission. Our team is more energized than ever to bring meaningful innovation to the field of structural heart interventions, where the risk of embolic debris, stroke, and brain ischemia remains a critical unmet need.”
Strategic Vision and Future Milestones
With the Series B2 round completed, Transverse Medical is focused on executing several key strategic initiatives over the next 12 to 18 months. These include:
- Expanding the clinical study footprint to additional centers of excellence internationally.
- Finalizing product enhancements based on feedback from early feasibility trials.
- Preparing for pivotal trials in the United States and other global markets.
- Initiating discussions with regulatory bodies to align on IDE submission requirements.
- Forging strategic partnerships with leading cardiovascular institutions, potential commercial partners, and key opinion leaders (KOLs).
- Strengthening the intellectual property portfolio to protect its technological innovations globally.
By maintaining a disciplined and patient-centric approach, Transverse Medical aims to set a new benchmark for safety and effectiveness in cerebral embolic protection, ultimately benefiting thousands of patients worldwide.
About POINT-GUARD™ and Transverse Medical, Inc.
Transverse Medical is an early-stage medical device company focused on the development of the POINT-GUARD™ Cerebral Embolic Protection medical device for use during Transcatheter Aortic Valve Replacements (TAVR) to protect patients from embolic debris (particles) that are dislodged and released (debris shower) into the cerebral blood flow that could lead to periprocedural stroke as a result of the TAVR procedure.
The next generation Point-Guard is a breakthrough advancement for complete Cerebral Embolic Protection of the brain and designed with operator ease of use and ability to accommodate variable arch anatomies with non-interference and full aortic arch stabilization.
